The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction

Withaar, Coenraad, Meems, Laura M G, Markousis-Mavrogenis, George, Boogerd, Cornelis J, Silljé, Herman H W, Schouten, Elisabeth M, Dokter, Martin M, Voors, Adriaan A, Westenbrink, B Daan, Lam, Carolyn S P, de Boer, Rudolf A·2021·Cardiovascular Research
DOI 10.1093/cvr/cvaa256

Cited by (223)

Items 101–200 of 223

  1. Epoxyeicosatrienoic acid: A potential therapeutic target of heart failure with preserved ejection fraction
    Min Zhang, Hongyang Shu, Chen Chen, Zuowen He, Zhou Zhou, Dao Wen Wang · 2022 · Biomedicine & Pharmacotherapy
  2. Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China
    Zhaohu Hao, Huang Xiao, Hailin Shao, He Feng · 2022 · Journal of Diabetes Research
  3. Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
    Kevin Yau, Ayodele Odutayo, Satya Dash, David Z.I. Cherney · 2023 · Canadian Journal of Cardiology
  4. Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists
    Massimo Volpe, Giovanna Gallo · 2020 · Cardiovascular Research
  5. Cardioprotection effect of Yiqi–Huoxue–Jiangzhuo formula in a chronic kidney disease mouse model associated with gut microbiota modulation and NLRP3 inflammasome inhibition
    Tong‐Tong Liu, Xiaoguang Lu, Wenya Gao, Yuanyuan Zhai, Han Li, Shangheng Li, Liping Yang, Fang Ma, Yongli Zhan, Huimin Mao · 2022 · Biomedicine & Pharmacotherapy
  6. Benefit of using interaction effects for the analysis of high-dimensional time-response or dose-response data for two-group comparisons
    Julia Duda, Carolin Drenda, Hue Kästel, Jörg Rahnenführer, Franziska Kappenberg · 2023 · Scientific Reports
  7. Effects of scutellarin on the mechanism of cardiovascular diseases: a review
    Xinyu Zhang, Tong Yin, Yincang Wang, Jiazhe Du, Jinjin Dou, Xiwu Zhang · 2024 · Frontiers in Pharmacology
  8. Comparison of Mouse Models of Heart Failure with Reduced Ejection Fraction
    Nabil V. Sayour, Tamás G. Gergely, Barnabás Váradi, Viktória É. Tóth, Bence Ágg, Tamás Kovács, Dániel Kucsera, Csenger Kovácsházi, Gábor B. Brenner, Zoltán Giricz et al. · 2024 · ESC Heart Failure
  9. Impact of Metabolic Dysfunction–associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure
    Bhavik Bansal, Fannie Lajeunesse‐Trempe, Neil Keshvani, Carl J. Lavie, Ambarish Pandey · 2025 · Canadian Journal of Cardiology
  10. Aging and HFpEF: Are we running out of time?
    Coenraad Withaar, Sunhuo Li, Laura M.G. Meems, Herman H.W. Silljé, Rudolf A. de Boer · 2022 · Journal of Molecular and Cellular Cardiology
  11. Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
    Yuling Jing, Ruixue Yang, Wen Chen, Qiang Ye · 2022 · Frontiers in Pharmacology
  12. Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model
    Sunhuo Li, Patrícia Gonçalves‐Rodrigues, Akash Deep Chakraborty, Cláudia Correia, Elisabeth M. Schouten, Maria Strömstedt, Lars Löfgren, Marie Persson, Linda Fredlund, Mattias Rohman et al. · 2025 · Pharmacological Research
  13. GLP-1 and the cardiovascular system
    Florian Kahles, Andreas L. Birkenfeld, Nikolaus Marx · 2026 · Journal of Clinical Investigation
  14. Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction
    Tianyu Wang, Qiang Yang, Xin-Yi Cheng, Jun-Can Ding, Peng-Fei Hu · 2024 · Heart Failure Reviews
  15. O-ring-induced transverse aortic constriction (OTAC) is a new simple method to develop cardiac hypertrophy and heart failure in mice
    Yasuhisa Nakao, Jun Aono, Mika Hamaguchi, Kayo Takahashi, Tomohisa Sakaue, Katsuji Inoue, Shuntaro Ikeda, Osamu Yamaguchi · 2022 · Scientific Reports
  16. Targeting the Metabolic-Inflammatory Circuit in Heart Failure With Preserved Ejection Fraction
    En Ping Yap, K.P. Myu Mai Ja, Chrishan J. A. Ramachandra · 2022 · Current Heart Failure Reports
  17. Targeting neutrophil extracellular traps: A novel strategy in hematologic malignancies
    Rongxing Liu, Jin Zhang, Fernando Rodrigues‐Lima, Jinhao Zeng, Qing Nian · 2024 · Biomedicine & Pharmacotherapy
  18. The inhibition of FTO attenuates the antifibrotic effect of leonurine in rat cardiac fibroblasts
    Yuwei Meng, Tianlan Xi, Jun Fan, Qiyu Yang, Jiadan Yang, Jiadan Yang · 2023 · Biochemical and Biophysical Research Communications
  19. In the heart and beyond: Mitochondrial dysfunction in heart failure with preserved ejection fraction (HFpEF)
    Nisha Bhattarai, Iain Scott · 2024 · Current Opinion in Pharmacology
  20. Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers
    Hend Samy Kheira, Gehad El‐Sayed, Mohamed El‐Adl · 2024 · Biochemical and Biophysical Research Communications
  21. Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure
    Gaurav Sharma, Shyam Sunder Chaurasia, Mark A. Carlson, Paras Kumar Mishra · 2024 · American Journal of Physiology-Heart and Circulatory Physiology
  22. Unlocking metabolic flexibility in heart failure with preserved ejection fraction: Bridging fundamental mechanisms to clinical innovation
    Junyan Xia, Yibing Nong, Jun Teng, S A Mohammed, Jing Liu, Yanting Pang, Sarah Costantino, Frank Thomas Ruschitzka, Nazha Hamdani, Mahmoud Abdellatif et al. · 2025 · iScience
  23. Mimicking Metabolic Disturbance in Establishing Animal Models of Heart Failure With Preserved Ejection Fraction
    Hui Li, Yiyuan Xia, Chunlei Xia, Zheng Li, Yi Ping Shi, Xiaobo Li, Junxia Zhang · 2022 · Frontiers in Physiology
  24. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
    Carlos Escobar, Domingo Andrés Pascual-Figal, Luís Manzano, Julio E. Núñez, Miguel Camafort · 2023 · Journal of Clinical Medicine
  25. Fighting HFpEF in women: taking aim at belly fat
    Coenraad Withaar, Laura M G Meems, Rudolf A. de Boer · 2020 · European Heart Journal
  26. SGLT2 inhibitors: how do they affect the cardiac cells
    Betül Rabia Erdoğan, Ebru Arioglu‐Inan · 2024 · Molecular and Cellular Biochemistry
  27. Daucosterol alleviates heart failure with preserved ejection fraction through activating PPARα pathway
    Jie Zhou, Bei Wang, Mengyao Wang, Yang Zha, Shengyuan Lu, Feng Zhang, Ying Peng, Yajun Duan, Dingrong Zhong, Shuang Zhang · 2024 · Heliyon
  28. Anti-Inflammatory and Anti-Oxidative Effects of GLP1-RAs and SGLT2i: The Guiding Star Towards Cardiovascular Protection in Type 2 Diabetes
    Livia M. R. Marcon, Alessio Mazzieri · 2025 · Immuno
  29. Heart failure: mechanistic insights and precision therapeutic strategies
    Fang Zhang, Xiang Zhang, Jing Jian, Xu Zeng, Chao Zheng, Yaxi Zhang, Jinquan Gao · 2025 · Frontiers in Cardiovascular Medicine
  30. Myocardial fat accumulation is associated with cardiac dysfunction in patients with type 2 diabetes, especially in elderly or female patients: a retrospective observational study
    Risa Kashiwagi-Takayama, Junji Kozawa, Yoshiya Hosokawa, Sarasa Kato, Satoshi Kawata, Harutoshi Ozawa, Ryohei Mineo, Chisaki Ishibashi, Megu Yamaguchi Baden, Ryuya Iwamoto et al. · 2023 · Cardiovascular Diabetology
  31. Astragaloside IV alleviates LPS-induced cardiomyocyte hypertrophy and collagen expression associated with CCL2-mediated activation of NF-κB signaling pathway
    Chanjuan Chai, Yao Sun, Rui‐Fang Chi, Huiyu Yang, Bin Yang, Bao Li · 2023 · Biochemical and Biophysical Research Communications
  32. Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice
    Angelo Di Vincenzo, Marika Crescenzi, Marnie Granzotto, Marco Vecchiato, Paola Fioretto, Roberto Vettor, Marco Rossato · 2024 · Journal of Endocrinological Investigation
  33. Exploring Sirtuins: New Frontiers in Managing Heart Failure with Preserved Ejection Fraction
    Ying Lü, Yongnan Li, Yixin Xie, Jiale Bu, Ruowen Yuan, Xiaowei Zhang · 2024 · International Journal of Molecular Sciences
  34. Dapagliflozin Treatment and Cardiovascular Outcome in RBP4/TTRVal30Met (Transthyretin Cardiac Amyloidosis) Mice
    Zonglin Li, Fang Lv, Xin Rong Wen, Chengcheng Guo, Li Li, Xiaoling Cai, Chu Lin, Mengqing Zhang, Wenjia Yang, Linong Ji · 2023 · ESC Heart Failure
  35. The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
    Xiangling Duan, Xiaomeng Zhang, Bao Sun · 2025 · Cardiovascular Diabetology
  36. Isosteviol sodium attenuates high fat/high cholesterol-induced myocardial dysfunction by regulating the Sirt1/AMPK pathway
    Ying Mei, Hui Zheng Hu, Liangjun Deng, Xiaoou Sun, Wen Tan · 2022 · Biochemical and Biophysical Research Communications
  37. Divergent effects of myostatin inhibition on cardiac and skeletal muscles in a mouse model of pressure overload
    Canxia Shi, Sietske N. Zijlstra, Sanne de Wit, Wouter C. Meijers, Joseph Pierre Aboumsallem, Herman H.W. Silljé, Rudolf A. de Boer · 2023 · American Journal of Physiology-Heart and Circulatory Physiology
  38. Relative contribution of correcting the diet and voluntary exercise to myocardial recovery in a two-hit murine model of heart failure with preserved ejection fraction
    Emylie-Ann Labbé, Sara-Ève Thibodeau, Élisabeth Walsh‐Wilkinson, Maude Chalifour, Pierre-Olivier Sirois, Juliette Leblanc, Audrey Morin-Grandmont, Marie Arsenault, Jacques Couët · 2025 · American Journal of Physiology-Heart and Circulatory Physiology
  39. Genetic Loss of Nicotinamide Nucleotide Transhydrogenase Prevents from Cardiometabolic Heart Failure with Preserved Ejection Fraction
    Mark E. Pepin, Sumra Nazir, Philipp J.M. Konrad, Friederike C. Schreiter, Matthias Dewenter, Johannes Backs · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  40. Cardiometabolic Phenotype in HFpEF: Insights from Murine Models
    Ekaterina Ogurtsova, Tatiana I. Arefieva, A. Yu. Filatova, N. V. Radyukhina, Artem G. Ovchinnikov · 2025 · Biomedicines
  41. Chitosan Versus Dapagliflozin in a Diabetic Cardiomyopathy Mouse Model
    Georgică Costinel Târtea, Aurel Popa‐Wagner, Veronica Sfredel, Smaranda Ioana Mitran, Alexandra Oltea Dan, Anca-Maria Țucă, Alexandra Nicoleta Preda, Victor Cornel Raicea, Eugen Nicolae Țieranu, Dragoș Constantin Cozma et al. · 2024 · International Journal of Molecular Sciences
  42. Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications
    Bogdan-Sorin Tudurachi, Larisa Anghel, Andreea Tudurachi, Radu Andy Sascău, Răzvan-Liviu Zanfirescu, Cristian Stătescu · 2024 · Biomedicines
  43. Exploring the therapeutic potential of tetrahydrobiopterin for heart failure with preserved ejection fraction: A path forward
    Weiyi Xia, Miao Zhang, Chang Liu, Sheng Wang, Aimin Xu, Zhengyuan Xia, Lei Pang, Yin Cai · 2024 · Life Sciences
  44. Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit
    Jordyn Thomas, Misha Dagan, Bing Hui Wang, S. Gutman, David M. Kaye · 2026 · Circulation Heart Failure
  45. HFpEF etiology – Can focus on sex-specific mechanisms deliver insights for all?
    Lea M.D. Delbridge, James R. Bell, Kate L. Weeks, Antonia J. A. Raaijmakers, Kimberley M. Mellor · 2022 · Journal of Molecular and Cellular Cardiology
  46. Potential Mechanisms of Epicardial Adipose Tissue Influencing Heart Failure with Preserved Ejection Fraction
    Qiuxuan Li, Ur Rehman Muhib, Xiaoteng Ma, Zaiqiang Liu, Fei Gao, Zhijian Wang · 2024 · Reviews in Cardiovascular Medicine
  47. The Loss of Gonadal Hormones Has a Different Impact on Aging Female and Male Mice Submitted to Heart Failure-Inducing Metabolic Hypertensive Stress
    Diwaba Carmel Teou, Emylie-Ann Labbé, Sara-Ève Thibodeau, Élisabeth Walsh‐Wilkinson, Audrey Morin-Grandmont, Ann-Sarah Trudeau, Marie Arsenault, Jacques Couët · 2025 · Cells
  48. Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review
    Mauro Gitto, Dimitrios A. Vrachatis, Gianluigi Condorelli, Konstantinos A. Papathanasiou, Bernhard Reimers, Spyridon G. Deftereos, Giulio Giuseppe Stefanini · 2021 · Cardiovascular & Hematological Agents in Medicinal Chemistry
  49. New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
    Juexing Li, Lei Zhou, Hui Gong · 2022 · Frontiers in Cardiovascular Medicine
  50. Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
    Khushali Trivedi, Vernon Wayne Dolinsky · 2026 · Canadian Journal of Physiology and Pharmacology
  51. Integrated analysis reveals ceRNA network of cardiac remodeling by SGLT2 inhibitor in middle-aged hypertensive rats
    Tianhua Xiong, Yuewang Jia, Fangyan Tan, Xianglin Long, Xin Yuan, Qiang She, Jianlin Du · 2023 · Biochemical and Biophysical Research Communications
  52. Biological sex, sex steroids and sex chromosomes contribute to mouse cardiac aging
    Audrey Morin-Grandmont, Élisabeth Walsh‐Wilkinson, Emylie-Ann Labbé, Sara-Ève Thibodeau, É. Dupont, Dominique K. Boudreau, Marie Arsenault, Yohan Bossé, Jacques Couët · 2024 · Aging
  53. A murine model of hypertensive heart disease in older women
    Audrey Morin-Grandmont, Élisabeth Walsh‐Wilkinson, Sara-Ève Thibodeau, Dominique K. Boudreau, Marie Arsenault, Yohan Bossé, Jacques Couët · 2024 · PeerJ
  54. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies
    Rayla Rodrigues Soares, Larissa Freitas Viggiani, Juliano Moreira Reis Filho, Julliane Vasconcelos Joviano‐Santos · 2024 · Chemico-Biological Interactions
  55. The effect of SGLT2i on in-hospital acute heart failure risk in acute myocardial infarction patients—a retrospective study
    Yi Zhun Zhu, Jiali Zhang, Hong Lan Jin, Yuan Ji, Fang-fang Wang · 2023 · Frontiers in Cardiovascular Medicine
  56. [Retracted] Effect of Dapagliflozin on Clinical Outcome after Drug‐Eluting Stent Implantation in Elderly T2DM Patients: A Real‐World Study
    Yuan Lin, Fang Zhou, Xihu Wang, Yaju Guo, Weiguo Chen · 2023 · Computational and Mathematical Methods in Medicine · Retracted
  57. Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis
    Anna Jia, Ming Yang, Tianhong Wang, Yusi Hua, Huimin Lu · 2025 · Frontiers in Cardiovascular Medicine
  58. Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
    Tatsuro Ibe, Barry A. Borlaug · 2025 · Annual Review of Medicine
  59. Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure
    Simone Pasquale Crispino, Annunziata Nusca, Aurora Ferro, Riccardo Cricco, Martina Ciancio, Andrea Segreti, Ilaria Cavallari, Mario Sabatino, Luciano Potena, Gian Paolo Ussia et al. · 2025 · Biomolecules
  60. Liraglutide alleviates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by enhancing mitophagy mediated by the AMPK-Parkin signaling pathway
    Yaxin Zhu, Wei Zhang, Hui-Lin Qu, Yue Zhang, Ruo-Qian Zhou, Ping Li, Fang Wang, Yan Zhang, Huihui Liu, Sha Li et al. · 2025 · World Journal of Diabetes
  61. Inflammation, metabolism, and aging in heart failure with preserved ejection fraction: Mechanisms and treatment perspectives
    Yaqun Teng, Weikang Bian, Qi Li, Jennifer E. Van Eyk, Xiaowei Yan, S Y Zhang · 2026 · Journal of Translational Internal Medicine
  62. Deep learning‐enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis
    Sheyla Barrado Ballestero, Sarah Torp Yttergren, Max Hahn, Marie Biviano Rosenkilde, Ditte Marie Jensen, Michael Søberg Christensen, Louise Thisted, Heidi Lindgreen Holmberg, Geoffrey Teixeira, Tor Biering‐Sørensen et al. · 2025 · British Journal of Pharmacology
  63. FRBM Mini REVIEW: Chemogenetic approaches to probe redox dysregulation in heart failure
    Ruby Guo, Fotios Spyropoulos, Thomas M. Michel · 2024 · Free Radical Biology and Medicine
  64. Divergent cardiac and renal effects of miR-181c-5p inhibition in a rodent heart failure model
    Jente R. A. Boen, Andreas B. Gevaert, Amélie Dendooven, Dustin N. Krüger, Michiel R. L. Tubeeckx, Jens Van fraeyenhove, Tine Bruyns, Vincent F. M. Segers, Emeline M. Van Craenenbroeck · 2024 · Frontiers in Cardiovascular Medicine
  65. Regulation of cardiac fibrosis in mice with TAC / DOCA ‐induced HF p EF by resistin‐like molecule gamma and adenylate cyclase 1
    Dawei Liu, Fanling Zeng, Zhiyu Chen, Zheng Hong Qin, Zhiqiang Liu · 2024 · FEBS Open Bio
  66. Combination of Empagliflozin and Liraglutide protects heart against isoproterenol-induced myocardial infarction in rats
    Neng Fisheri Kurniati, Almira Fathadina · 2023 · Pharmacia
  67. Insights into Myocardial Fibrosis in Advanced Chronic Kidney Disease Using Human Tissue
    Nandan Kumar Mondal, Carl Peter Walther · 2023 · Kidney360
  68. Efficacy of Semaglutide and Other GLP-1 Agonists in Patients with Heart Failure With Preserved Ejection Fraction and Obesity: A Systemic Review and Meta-Analysis.
    Mohammed S. Beshr, Rana Hasen Shembesh, Arwi Omar Kara, Abdelaziz H Salama, Esraa Arhaym, Maram Abuajamieh, Muhammed Elhadi · 2025 · PubMed
  69. Sexual dimorphism in animal models of heart failure with preserved ejection fraction
    Maria Bauer, Mahin Gadkari, Marta Martinez Yus, Lakshmi Santhanam, Jochen Steppan · 2025 · Journal of Applied Physiology
  70. Multimodal imaging reveals distinct cardiac benefits of dulaglutide versus dapagliflozin in a mouse model of glucotoxic cardiomyopathy
    Michaël Joubert, Simon Ducheix, Xavier Prieur, Bertrand Cariou, Alain Manrique · 2025 · Diabetes Obesity and Metabolism
  71. Effects of dapagliflozin on ventricular remodeling and prognosis in older females with heart failure with preserved ejection fraction: A single-center prospective study
    Jiajia Huang, Jie Chen, Suyan Xu, Hongyan Zhang, Ming Ni, Aifeng Wang, Yanan Shi · 2025 · Experimental Gerontology
  72. Liraglutide Ameliorates Methotrexate‐Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF‐α/NF‐κB Signaling Inflammatory Pathway
    Dina Adam Ali, Dalia Ibrahim, Eman Kolieb, Islam Omar Abdel Fattah, Shymaa Ahmed Maher, Amr Elkelish, Nasir A. Abdalneim, Nadia Abozied · 2025 · Journal of Biochemical and Molecular Toxicology
  73. Heart Failure: Epidemiology, Pathophysiology, and Management
    Yujian Fan, Zhihua Yang, Qing Li, Meng Sun, Yumeng Pu, Ke Zhao, Yu Bao, Xianliang Wang, Jingyuan Mao, Zhiqiang Zhao · 2026 · MedComm
  74. Metabolic Syndrome Nonalcoholic Steatohepatitis Male Mouse With Adeno‐Associated Viral Renin as a Novel Model for Heart Failure With Preserved Ejection Fraction
    Yuji Shi, Patricia Perez‐Bonilla, Xian CHEN, Kelly Tam, Mackenzie Marshall, Jeffrey Morin, Brianna LaViolette, Nouaying R. Kue, Federico Damilano, Russell Miller et al. · 2024 · Journal of the American Heart Association
  75. Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models
    Zhao Gao, Sushan Cao, Haiqing Yuan, Jim Zhen Wu, Gang Zou · 2025 · International Immunopharmacology
  76. Effects of Combination Treatment with Leptin and Liraglutide on Glucose Metabolism in Insulin-Dependent Diabetic Mice
    Linlin Fu, Mariko Sugiyama, Shahriar Kamal, Tsubasa Ide, Tadashi Takeda, Mitsuhiro Kuno, Hiroshi Takagi, Teruhiko Koike, Hiroshi Arima, Ryoichi Banno · 2025 · International Journal of Molecular Sciences
  77. Clinical Effects of Sacubitril/Valsartan Combined with Dapagliflozin in Patients with Diabetes and ST-segment Elevation Myocardial Infarction
    Zhengbin Wang, Zhifang Li, Yiming Hou, Panpan Wang, Zhikang Zhao, Shuo Wang, Li Ting Huang, Lei Wang · 2023 · Cardiovascular Innovations and Applications
  78. Hexokinase-1 mitochondrial dissociation and protein O-GlcNAcylation drive heart failure with preserved ejection fraction
    Yuki Tatekoshi, Jason Solomon Shapiro, Mingyang Liu, George M Bianco, Ayumi Tatekoshi, Adam De Jesus, Navid Koleini, John Andrew Wasserstrom, WOLFGANG H. DILLMANN, Samuel Edward Weinberg et al. · 2023 · Research Square
  79. Semaglutide in Heart Failure With Preserved Ejection Fraction
    Kamil Aleksander Kobak, Ying Ann Chiao · 2023 · JACC Basic to Translational Science
  80. Selective class IIa HDAC inhibition reverses diastolic dysfunction in cardiometabolic HFpEF
    Jiale Huang, Friederike C. Schreiter, Junyu Fan, Zihao Chen, Harikrishnareddy Paluvai, Coenraad Withaar, Christian U. Oeing, Ali R. Saadatmand, Eric Schoger, Shaza Haydar et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  81. Animal models for development of anti-obesity drugs in the age of GLP-1 agents
    Alexander E. Culver, Keith R. Stayrook, Michele M. Comerota, Adrian L. Oblak, Thomas P. Burris · 2025 · Expert Opinion on Drug Discovery
  82. TyG ‐ BMI index as a valuable risk of acute kidney injury in patients with heart failure: Insights from the MIMIC ‐ IV and eICU cohorts
    Yiming Hua, Ze Chen, Lele Cheng, Ning Ding, Yifei Xie, Hao Wu, Huaizhi Jing, Yu Song Xu, Yue Wu, Beidi Lan · 2025 · Journal of Diabetes Investigation
  83. Integrative gene-metabolite network analysis of GLP-1 receptor agonists and related incretin pathways in cardiometabolic health
    Zofia Wicik, Anna Nowak-Szwed, Ceren Eyileten, Harald Sourij, Dirk von Lewinski, Svjatoslavs Kistkins, Joanna Borkowska, Marek A Postula · 2025 · npj Systems Biology and Applications
  84. Addressing Key Limitations of Diastolic Function Assessment in Mouse Echocardiography by Enabling Robust Retrospective Analysis From a Standard Imaging View
    Michael Marterstock, Antje Schauer, Alina Maslakova, Annett Opitz, Peter Dieterich, Stephan Speier, Susanne Kämmerer, Peter Mirtschink, Irakli Kopaliani, Andreas Deußen · 2026 · Acta Physiologica
  85. Assessment of Cardiac Frailty in Preclinical Models of Heart Failure and Ageing – Parallels Between Discovery and the Clinic
    Abhipree Sharma, Julee McDonagh, Doan T M Ngo, Miles J. De Blasio, Caleb Ferguson, Rebecca Helen Ritchie · 2026 · Heart Lung and Circulation
  86. Sex-specific responses in the early stages of diet-induced cardiovascular-kidney-metabolic syndrome
    Abhipree Sharma, Minh Deo, K C Khe Tran, N. Jennifer Tang, Tayla Bishop, Alexander N. Parker, Nimna Perera, Anida Mesinovic, Ryan D. Gillis, Md Abdullah Al Mamun et al. · 2026 · American Journal of Physiology-Heart and Circulatory Physiology
  87. Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue
    Xinning Li, Yanmeng Liu, Fan Wang, Feifei Zhang, Lina Zhang, Yi Dang, Xiaoyong Qi · 2026 · Cardiovascular Drugs and Therapy
  88. Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy
    Jakub Benko, Matej Samoš, Tomáš Bolek, Dana Prídavková, Jakub Jurica, Martin Jozef Péč, Péter Galajda, Marian Mokáň · 2022 · Journal of Diabetes Research
  89. Modeling heart failure with preserved ejection fraction in rodents: Where do we stand?
    Chun Chou, Michael T. Chin · 2022 · Frontiers in Drug Discovery
  90. Sex, drugs and high fat diet: Characterizing HFpEF in female C57BL6/J mice
    Joshua G. Travers, Emma Louise Robinson · 2024 · Journal of Molecular and Cellular Cardiology Plus
  91. SCORED and SOLOIST: the next scores for SGLT2 inhibitors
    Johann K Bauersachs · 2020 · Cardiovascular Research
  92. Contribution of Ketone Oxidation on Energy Production in the Failing Heart
    Simran Pherwani · 2021 · ERA: Education and Research Archive (University of Alberta)
  93. Advances in Research on Heart Failure with Preserved Ejection Fraction
    小利 赵 · 2022 · Advances in Clinical Medicine
  94. Sodium–Glucose Cotransporter-2 Inhibitors: An Old Medication With New Indication in Heart Failure With Preserved Ejection Fraction
    Mohamed Toufic El Hussein, Cassandra Reeves · 2023 · The Journal for Nurse Practitioners
  95. Cardio-oncology: new insights into association and interaction between cardiovascular disease and cancer
    Canxia Shi · 2023 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  96. Schaftoside Improves Hfpef Through Regulation the Autophagy-Lysosome Pathway by Allosterically Targeting Camkii-Δ
    Yan Liu, haiying Zhang, Yanan Gao, Min Zhang, Zhexin Yuan, Yu Chen, Aiping Wang, Xinxing Liu, Shunchang Ji, Jianfeng Jin et al. · 2024 · SSRN Electronic Journal
  97. Canagliflozin protects cardiovascular function in type 2 diabetic coronary artery disease by regulating natriuretic peptide B
    Jiarui Zhang, Lichenlu Huang, Yongqin Zheng, Ji Young Yang, Xiaopei Wu, Jun-Dong He · 2025 · Journal of Diabetes Investigation
  98. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review
    Amir Saeed, Bilal Younas, Ali Rohan, Usman Haider, Asad Mukhtar, Marriam Nazir, Maryam Maryam · 2025 · Cureus
  99. IMPACT OF CELEBRITY STATEMENTS ON INTERNET SEARCHES ON THE USE OF SEMAGLUTIDE FOR WEIGHT LOSS
    Local Health Unit of Trapani, ASP Trapani, Trapani, Italy, Sandro Provenzano, Omar Enzo Santangelo, Regional Health Care and Social Agency of Lodi, ASST Lodi, Lodi, Italy · 2025 · Avicenna Bulletin
  100. A female-specific rabbit model of heart failure with preserved ejection fraction
    Liyang Zhang, Xiaochun Li, Taiga Andersson, Anxhela Kote, Minjing Yang, Po-Tseng Lee, James Edward Tisdale, Zhenhui Chen, Thomas H. Everett, Michael C. Fishbein et al. · 2025 · Heart Rhythm